Italia markets closed

TBIO Oct 2024 2.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,09000,0000 (0,00%)
In data: 01:08PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0900
Aperto0,1500
Denaro0,0000
Domanda0,0000
Prezzo d'esercizio2,50
Scadenza2024-10-18
Min-Max giorno0,0900 - 0,1500
Contratto - Min-MaxN/D
Volume6
Open Interest24
  • GlobeNewswire

    Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS

    New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology WorkstationSAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® NGS Library Prep kit for Whole Genome Sequencing on the BioXp 3250 and BioXp 9600 systems. This NGS libr

  • GlobeNewswire

    Telesis Bio Appoints William J. Kullback Chief Financial Officer

    SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. “Bill’s deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to

  • GlobeNewswire

    Telesis Bio Reports Second Quarter 2023 Financial Results

    -- Total revenue of $8.7M in 2QFY23 - increased by 53% year over yearSAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023. “We achieved important milestones this quarter toward our path to profitability by delivering revenue growth again while expanding gross margins and reducing operating expenses. In addition, we raised capital during the qu